HUP0004896A3 - Fusion proteins comprising hiv-1 tat and/or nef proteins - Google Patents

Fusion proteins comprising hiv-1 tat and/or nef proteins

Info

Publication number
HUP0004896A3
HUP0004896A3 HU0004896A HUP0004896A HUP0004896A3 HU P0004896 A3 HUP0004896 A3 HU P0004896A3 HU 0004896 A HU0004896 A HU 0004896A HU P0004896 A HUP0004896 A HU P0004896A HU P0004896 A3 HUP0004896 A3 HU P0004896A3
Authority
HU
Hungary
Prior art keywords
proteins
tat
hiv
nef
fusion proteins
Prior art date
Application number
HU0004896A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10819735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0004896(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of HUP0004896A1 publication Critical patent/HUP0004896A1/hu
Publication of HUP0004896A3 publication Critical patent/HUP0004896A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HU0004896A 1997-09-26 1998-09-17 Fusion proteins comprising hiv-1 tat and/or nef proteins HUP0004896A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9720585.0A GB9720585D0 (en) 1997-09-26 1997-09-26 Vaccine
PCT/EP1998/006040 WO1999016884A1 (en) 1997-09-26 1998-09-17 Fusion proteins comprising hiv-1 tat and/or nef proteins

Publications (2)

Publication Number Publication Date
HUP0004896A1 HUP0004896A1 (hu) 2001-04-28
HUP0004896A3 true HUP0004896A3 (en) 2003-05-28

Family

ID=10819735

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004896A HUP0004896A3 (en) 1997-09-26 1998-09-17 Fusion proteins comprising hiv-1 tat and/or nef proteins

Country Status (28)

Country Link
EP (1) EP1015596B2 (hu)
JP (2) JP2001518300A (hu)
KR (1) KR100554487B1 (hu)
CN (1) CN1188519C (hu)
AR (2) AR017147A1 (hu)
AT (1) ATE338128T1 (hu)
AU (1) AU746564B2 (hu)
BR (1) BR9812547A (hu)
CA (1) CA2305013C (hu)
CO (1) CO4810339A1 (hu)
CZ (1) CZ302878B6 (hu)
DE (1) DE69835756T3 (hu)
DK (1) DK1015596T4 (hu)
ES (1) ES2272012T5 (hu)
GB (1) GB9720585D0 (hu)
HK (1) HK1030431A1 (hu)
HU (1) HUP0004896A3 (hu)
IL (1) IL135102A0 (hu)
NO (2) NO328824B1 (hu)
NZ (1) NZ503482A (hu)
PL (1) PL195243B1 (hu)
PT (1) PT1015596E (hu)
SA (1) SA98190877B1 (hu)
SI (1) SI1015596T2 (hu)
TR (1) TR200000864T2 (hu)
TW (1) TW499436B (hu)
WO (1) WO1999016884A1 (hu)
ZA (1) ZA988789B (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
CA2363118A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
JP2002541786A (ja) * 1999-04-12 2002-12-10 モデックス テラピューティク ソシエテ アノニム 遺伝子治療における使用のための一過性不死化細胞
ATE306938T1 (de) * 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa Verwendung von cpg als adjuvans für hivimpstoff
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
CN1326873C (zh) * 2000-01-31 2007-07-18 史密丝克莱恩比彻姆生物有限公司 用于hiv预防或治疗性免疫的疫苗
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
HU230488B1 (hu) 2001-11-21 2016-08-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
KR100466382B1 (ko) * 2002-01-08 2005-01-14 주식회사 엘지생명과학 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
NZ536499A (en) 2002-05-16 2008-04-30 Bavarian Nordic As Fusion protein comprising the amino acid sequence of at least four different HIV proteins selected from Vif, Vpr, Vpu, Vpx, Rev, Tat and Nef, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
WO2005090968A1 (en) 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
IL286053B2 (en) * 2005-10-18 2023-03-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
BRPI0819774A2 (pt) 2007-11-28 2014-10-14 Univ Pennsylvania Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
SI2220241T1 (sl) 2007-11-28 2017-02-28 The Trustees Of The University Of Pennsylvania Adenovirus, ki obsega kapsidni heksonski protein opičjega E adenovirusa SAdV-39, in njegove uporabe
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
KR20170078862A (ko) 2008-05-16 2017-07-07 타이가 바이오테크놀로지스, 인코포레이티드 항체 및 그 제조 방법
CA2731767C (en) 2008-07-21 2016-12-06 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method for preparing the same
EP3916010A1 (en) 2008-08-28 2021-12-01 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
JP5809978B2 (ja) 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−４３、−４５、−４６、−４７、−４８、−４９および−５０ならびにそれらの用途
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
WO2010138675A1 (en) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
EP2643465B1 (en) 2010-11-23 2016-05-11 The Trustees Of The University Of Pennsylvania Subfamily e simian adenovirus a1321 and uses thereof
WO2012124998A2 (ko) * 2011-03-15 2012-09-20 연세대학교 산학협력단 바이오핀
SG11201407343XA (en) 2012-05-18 2014-12-30 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
WO2014012090A1 (en) 2012-07-13 2014-01-16 The Broad Institute, Inc. Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
EP3868387A1 (en) 2012-07-20 2021-08-25 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
CA2926221A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
MX365658B (es) 2014-05-13 2019-06-10 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.
JP6886406B2 (ja) * 2015-04-16 2021-06-16 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク コバルトポルフィリン・リン脂質コンジュゲート及びポリヒスチジンタグを含むナノ構造体
US11207421B2 (en) 2015-04-16 2021-12-28 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
KR20240011714A (ko) 2021-04-27 2024-01-26 제너레이션 바이오 컴퍼니 치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
AU681572B2 (en) * 1991-10-21 1997-09-04 Med Immune, Inc. Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
DK0656950T3 (da) * 1992-08-21 1999-07-19 Biogen Inc TAT-afledte transportpolypeptider
ATE302854T1 (de) * 1993-01-26 2005-09-15 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
JPH11501310A (ja) * 1995-03-08 1999-02-02 ネオバック レトロウイルスの調節タンパク質から誘導された無毒の免疫原、抗体、製造方法およびそれらを含んでなる医薬組成物
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
JP2009213492A (ja) 2009-09-24
DK1015596T4 (da) 2010-07-12
JP2001518300A (ja) 2001-10-16
CZ302878B6 (cs) 2012-01-04
CA2305013C (en) 2008-04-08
DE69835756T2 (de) 2007-09-13
ZA988789B (en) 2000-03-29
CN1279718A (zh) 2001-01-10
KR20010024287A (ko) 2001-03-26
KR100554487B1 (ko) 2006-03-03
GB9720585D0 (en) 1997-11-26
DK1015596T3 (da) 2007-01-02
NO328824B1 (no) 2010-05-25
ES2272012T3 (es) 2007-04-16
CA2305013A1 (en) 1999-04-08
AR080331A2 (es) 2012-03-28
WO1999016884A1 (en) 1999-04-08
TR200000864T2 (tr) 2000-08-21
SI1015596T1 (sl) 2007-02-28
EP1015596B1 (en) 2006-08-30
NO20001508D0 (no) 2000-03-23
PT1015596E (pt) 2006-12-29
PL195243B1 (pl) 2007-08-31
BR9812547A (pt) 2000-07-25
CZ20001091A3 (cs) 2000-09-13
SA98190877B1 (ar) 2006-09-10
NO20001508L (no) 2000-05-18
NZ503482A (en) 2001-09-28
ES2272012T5 (es) 2010-07-06
AU746564B2 (en) 2002-05-02
AR017147A1 (es) 2001-08-22
PL339432A1 (en) 2000-12-18
DE69835756D1 (de) 2006-10-12
CN1188519C (zh) 2005-02-09
HUP0004896A1 (hu) 2001-04-28
DE69835756T3 (de) 2010-09-30
EP1015596A1 (en) 2000-07-05
IL135102A0 (en) 2001-05-20
NO20076467L (no) 2000-05-18
EP1015596B2 (en) 2010-04-14
AU1025599A (en) 1999-04-23
SI1015596T2 (sl) 2010-07-30
TW499436B (en) 2002-08-21
CO4810339A1 (es) 1999-06-30
ATE338128T1 (de) 2006-09-15
HK1030431A1 (en) 2001-05-04

Similar Documents

Publication Publication Date Title
HUP0004896A3 (en) Fusion proteins comprising hiv-1 tat and/or nef proteins
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
GB9718609D0 (en) Fusion protein
DE69832542D1 (de) Fusionsimplantat
IS4814A (is) Tilbúin HIV gen
ZA975889B (en) HIV envelope polypeptides and vaccine.
EP0962763A4 (en) Differential
GB9705903D0 (en) VP22 Proteins and uses thereof
EP0626450A3 (en) Fusion proteins containing the enzyme ubiquitin conjugate (E2).
IL122898A0 (en) Allergan -XCD32 fusion proteins
AU9798398A (en) Gfp-annexin fusion proteins
CZ2000522A3 (cs) Farmaceutický prostředek na bázi piperidinalkanolového antihistaminika a použití
GB2336844B (en) Anti-hiv peptides and proteins
AU2002300390A1 (en) Fusion proteins comprising HIV-1 TAT and/or NEF proteins
EP1037963A4 (en) X-RAY CRYSTAL COMPRISING HIV-1 GP120
IL149202A0 (en) Hedgehog fusion proteins and uses
SI1121382T1 (sl) Fuzijski proteini interferona-beta in uporabe
AU7960298A (en) Two human membrane fusion proteins
GB9713150D0 (en) Fusion proteins
BR7501787U (pt) Faca soldada
IL120413A0 (en) Novel PKA-binding proteins and uses thereof
IL120392A0 (en) Novel PKA-binding proteins and uses thereof
GB9812756D0 (en) Assay procedure for identifying inhibitors of the nuclease-inhibitory function of the human immunodeficiency virus tat protein
BR7501788U (pt) Faca calçada por brasagem
GB9703104D0 (en) Proteins

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished